Anthem leaving Ohio ACA marketplace

Anthem has announced its exiting the Affordable Care Act exchange in all but one Ohio county, citing the uncertainty over whether the Trump administration will continue to pay cost-sharing reduction subsidies to insurers.

According to the Cleveland Plain-Dealer, Anthem is leaving the door open for a quick return by offering ACA-compliant individual policies in one small area, Pike County. Due to other planned shifts, however, the move could leave up to 18 counties in the state at risk of lacking an ACA insurer next year.

In the statement announcing the withdrawal, Anthem said a stable insurance market "is dependent on products that create value for consumers through the broad spreading of risk and a known set of conditions upon which rates can be developed. Today, planning and pricing for ACA-compliant health plans has become increasingly difficult due to the shrinking individual market as well as continual changes in federal operations, rules and guidance."

Both Democrats and Republicans representing the state pounced on announcement as proof the other side is preventing needed changes to the ACA markets.

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.